Literature DB >> 16682586

Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema.

Se Woong Kang1, Ho-Seok Sa, Hee Yoon Cho, Jong In Kim.   

Abstract

OBJECTIVE: To evaluate the clinical outcomes of macular laser photocoagulation after the intravitreal injection of 4 mg of triamcinolone acetonide (IVTA) for diffuse diabetic macular edema (DME).
METHODS: Eighty-six eyes of 74 patients with diffuse DME were randomized into 2 groups. The laser group eyes (n = 48) were subjected to a macular grid laser photocoagulation 3 weeks after IVTA. The control group eyes (n = 38) underwent only IVTA. Both groups were compared with regard to the changes in visual acuity and central macular thickness at 3 weeks, 3 months, and 6 months after IVTA.
RESULTS: The mean central macular thickness before, 3 weeks after, and 3 and 6 months after IVTA were 538, 250, 295, and 301 mum in the laser group vs 510, 227, 302, and 437 mum in the control group, respectively. The logMAR visual acuities were not significantly different between the 2 groups at baseline and at 3 weeks after IVTA but were significantly better in the laser group at 3 (P = .02) and 6 months (P<.001) after IVTA.
CONCLUSIONS: Macular laser coagulation effectively maintains improved visual acuity after IVTA for diffuse DME and is believed to reduce recurrent DME after IVTA.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16682586     DOI: 10.1001/archopht.124.5.653

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  28 in total

1.  Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.

Authors:  Michael J Elman; Lloyd Paul Aiello; Roy W Beck; Neil M Bressler; Susan B Bressler; Allison R Edwards; Frederick L Ferris; Scott M Friedman; Adam R Glassman; Kellee M Miller; Ingrid U Scott; Cynthia R Stockdale; Jennifer K Sun
Journal:  Ophthalmology       Date:  2010-04-28       Impact factor: 12.079

2.  Macular ischemia and outcome of vitrectomy for diabetic macular edema.

Authors:  Jaeryung Kim; Se Woong Kang; Dong Hoon Shin; Sang Jin Kim; Ga Eun Cho
Journal:  Jpn J Ophthalmol       Date:  2015-08-01       Impact factor: 2.447

3.  Intravitreal triamcinolone for diffuse diabetic macular oedema.

Authors:  A Longo
Journal:  Br J Ophthalmol       Date:  2006-09       Impact factor: 4.638

4.  Combined triamcinolone acetonide injection and grid laser photocoagulation: a promising treatment for diffuse diabetic macular oedema?

Authors:  Tomohiro Iida
Journal:  Br J Ophthalmol       Date:  2007-04       Impact factor: 4.638

5.  Vessel diameter study: intravitreal vs posterior subtenon triamcinolone acetonide injection for diabetic macular edema.

Authors:  M M Kurt; O Çekiç; Ç Akpolat; M Aslankurt; M Elçioğlu
Journal:  Eye (Lond)       Date:  2017-03-24       Impact factor: 3.775

Review 6.  Bioactive lipids and pathological retinal angiogenesis.

Authors:  Khaled Elmasry; Ahmed S Ibrahim; Samer Abdulmoneim; Mohamed Al-Shabrawey
Journal:  Br J Pharmacol       Date:  2018-11-19       Impact factor: 8.739

7.  Pretreatment of posterior subtenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema.

Authors:  Masahiko Shimura; Toru Nakazawa; Kanako Yasuda; Takashi Shiono; Kohji Nishida
Journal:  Br J Ophthalmol       Date:  2006-10-31       Impact factor: 4.638

8.  Current treatments in diabetic macular oedema: systematic review and meta-analysis.

Authors:  John Alexander Ford; Noemi Lois; Pamela Royle; Christine Clar; Deepson Shyangdan; Norman Waugh
Journal:  BMJ Open       Date:  2013-03-01       Impact factor: 2.692

9.  Single injection of triamcinolone versus three repeated injections of bevacizumab for treatment of diabetic macular edema.

Authors:  Mehmet Taş; Veysi Oner; Mehmet Fuat Alakuş; Fatih Mehmet Türkcü; Yalçın Işcan; Kemal Yüksel
Journal:  Int Ophthalmol       Date:  2013-01-19       Impact factor: 2.031

10.  Diabetic retinopathy - An update.

Authors:  Abdulrahman A Alghadyan
Journal:  Saudi J Ophthalmol       Date:  2011-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.